Tjoapack invests in automated injectables packaging capabilities

The packaging lines are projected to be completed by the end of 2021

Tjoapack is investing in its automated packaging capabilities to meet growing customer demand for pre-filled syringes and vials.

The automated packaging line for vials will start operations in Q1 2021 and will increase its capacity to over 12 million vials per year. Its pre-filled syringes (PFS) capabilities are expected to be operational by Q4 of 2021.

The automated PFS packaging line will have an initial capacity for 7 million syringes per year and will assemble, automate insertion of plunger rods and back-stops, carry out inline labelling and complete coding and vision control.

The investment follows increased demand from existing and new customers for pre-filled and vial packaging in line with the prevalence of chronic diseases that require injectable therapies.

This latest addition to Tjoapack’s service offering follows the recent investment by private equity firm and healthcare specialists, Ampersand Capital Partners.

Dexter Tjoa, CEO at Tjoapack said: “At Tjoapack we’re committed to ensuring we consistently bolster our offering and deliver the efficient and flexible services that our clients expect. The investment from Ampersand allows us to build on our strong foundations, expand our service offering, and ensure we continue to meet customer demand.

Dexter added: “As new therapies emerge to address unmet patient needs for chronic ailments the demand for contract packaging organisation that can handle syringes and vials will continue to rise.

Companies